New York State Common Retirement Fund Has $513,000 Stock Holdings in AngioDynamics, Inc. (NASDAQ:ANGO)

Key Points

• The New York State Common Retirement Fund increased its holdings in AngioDynamics, Inc. by 667% in the first quarter, bringing its total stake to 54,635 shares valued at $513,000.
• AngioDynamics reported a quarterly revenue of $80.16 million, surpassing analyst estimates, and earned an EPS of ($0.03), which was better than the estimated ($0.12).
• Recently, several research analysts have given AngioDynamics a "buy" rating, with target prices ranging from $16.00 to $24.00.

New York State Common Retirement Fund grew its stake in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) by 667.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 54,635 shares of the medical instruments supplier's stock after buying an additional 47,512 shares during the period. New York State Common Retirement Fund owned 0.13% of AngioDynamics worth $513,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Quinn Opportunity Partners LLC bought a new stake in shares of AngioDynamics during the 4th quarter valued at about $92,000. ProShare Advisors LLC bought a new stake in shares of AngioDynamics during the 4th quarter valued at about $100,000. Graham Capital Management L.P. bought a new stake in shares of AngioDynamics during the 4th quarter valued at about $106,000. OneDigital Investment Advisors LLC boosted its position in shares of AngioDynamics by 14.0% during the 4th quarter. OneDigital Investment Advisors LLC now owns 12,137 shares of the medical instruments supplier's stock valued at $111,000 after purchasing an additional 1,490 shares in the last quarter. Finally, Cerity Partners LLC boosted its position in shares of AngioDynamics by 22.0% during the 1st quarter. Cerity Partners LLC now owns 12,929 shares of the medical instruments supplier's stock valued at $121,000 after purchasing an additional 2,333 shares in the last quarter. Institutional investors and hedge funds own 89.43% of the company's stock.

Analyst Ratings Changes

ANGO has been the topic of several research analyst reports. Lake Street Capital initiated coverage on AngioDynamics in a research report on Wednesday, July 16th. They set a "buy" rating and a $24.00 target price on the stock. HC Wainwright restated a "buy" rating and set a $16.00 target price on shares of AngioDynamics in a research report on Wednesday, July 16th. Finally, Canaccord Genuity Group upped their target price on AngioDynamics from $15.00 to $17.00 and gave the company a "buy" rating in a research report on Wednesday, July 16th.

AngioDynamics Stock Performance

Shares of NASDAQ:ANGO opened at $9.22 on Friday. The business's 50 day simple moving average is $9.83 and its two-hundred day simple moving average is $10.06. The firm has a market cap of $374.61 million, a P/E ratio of -11.11 and a beta of 0.60. AngioDynamics, Inc. has a 52-week low of $5.83 and a 52-week high of $13.50.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last announced its quarterly earnings results on Tuesday, July 15th. The medical instruments supplier reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.09. The business had revenue of $80.16 million for the quarter, compared to analyst estimates of $74.26 million. AngioDynamics had a negative return on equity of 3.20% and a negative net margin of 11.62%. The company's quarterly revenue was up 13.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.06) earnings per share. On average, equities analysts forecast that AngioDynamics, Inc. will post -0.37 earnings per share for the current fiscal year.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.

Want to see what other hedge funds are holding ANGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AngioDynamics, Inc. (NASDAQ:ANGO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.